Compare American Financial Group Inc (AFG) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Financial Group Inc vs Enveric Biosciences Inc — how do they compare? American Financial Group Inc trades at $141.19 (market cap $11.86B), while Enveric Biosciences Inc trades at $1.37 (market cap $5.84M). The key difference: American Financial Group Inc is far larger — about 2030.8× Enveric Biosciences Inc's market cap, and American Financial Group Inc pays a 2.46% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| AFG | ENVB | |
|---|---|---|
Market Cap | $11.86B | $5.84M |
Sector | Financials | Health |
52-Week High | $148.71 | $17.40 |
52-Week Low | $122.42 | $1.28 |
Enterprise Value | $12.33B | $932.52K |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFG trades at $142.80, up 0.04% with a bullish technical outlook. The stock shows strong profitability with 10.84% net margin and 19.38% ROE, though Q1 2026 earnings missed estimates. Recent dividend declarations of $0.88 per share highlight shareholder returns. Analyst consensus is mixed with 41% buy ratings and a $149 price target, representing 4.3% upside from current levels.
AFG offers moderate upside potential with solid fundamentals and consistent dividends, but faces execution risks after recent earnings miss. The insurance sector exposure provides stability, though competitive pressures and regulatory changes remain key watchpoints for investors seeking steady returns with income generation.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
